nivolumab

targets

all catalysts(86)

News(10)

• Akeso, Summit cancer drug confirms lung cancer survival benefit
  A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.
  biopharma_dive · 20h ago
• Replimune’s melanoma drug would have been rejected again if not for senior CBER official
  The FDA’s primary review team found that Replimune hadn’t sufficiently addressed deficiencies that had been pointed out in the two prior rejection letters for the melanoma therapy Tudriqev.
  biospace · 21h ago
• Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial fails
  BMS is barreling toward a clinical trial readout that an H.C. Wainwright analyst believes could contribute to the return of mergers between mega-cap drugmakers.
  biospace · 2d ago
• Capricor, Replimune reviews signal FDA’s return to reliability but every application will stand alone
  Following a tumultuous stretch under ex-Commissioner Marty Makary, current FDA leadership is working to restore reliability, integrity and transparency to the agency—but experts say that doesn’t ne…
  biospace · 11d ago
• AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
  An interim data check revealed that survival goals were likely to be missed by volrustomig, one in a list of new drugs the U.K. company is leaning on to meet an $80 billion sales goal.
  biopharma_dive · 17d ago
• BMS picks Texas for new $2.3B manufacturing campus
  Bristol Myers Squibb’s $2.3 billion Houston manufacturing campus is part of the company’s larger $40 billion investment designed to bolster American innovation and manufacturing.
  biospace · 24d ago
• Replimune rebounds to win FDA approval of melanoma drug
  The accelerated clearance follows two earlier rejections and the support of an advisory panel that disputed the arguments of FDA scientists.
  biopharma_dive · 28d ago
• Third time’s the charm for Replimune as melanoma drug earns FDA greenlight
  Replimune’s immunotherapy for advanced melanoma faced a perilous regulatory road with two previous rejections, but the drug—to be marketed as Tudriqev—prevailed with strong support from oncologists…
  biospace · 28d ago
• FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma
  The U.S. Food and Drug Administration today granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral therapy for the treatment of advanced,…
  fda_press · 28d ago
• No deal between AstraZeneca and BMS, senior source insists: Reuters
  Reuters has deflated rumors that AstraZeneca and Bristol Myers Squibb are discussing a possible merger, letting the air out of industry-wide speculation over what could have been the largest deal i…
  biospace · 29d ago